Leukaemia: artificial intelligence provides support in diagnostics

IT specialists and physicians develop new method for recognising genetic aberrations

16-Jan-2024 - Decisions on treatment for patients with acute myeloid leukemia(AML) – a highly aggressive form of leukemia– are based, among other things, on a series of certain genetic features of the disease; but at the time when a diagnosis is made, this information is not available. However, evidence of ...

Detailed tumour profiling

Better determine which treatment will best match every patient’s cancer and thus be most effective.

25-Jan-2021 - As part of a clinical study involving patients from the University Hospitals in Zurich and Basel, researchers are conducting a thorough and highly precise investigation into the molecular and functional properties of tumours. Their goal is to help physicians to better determine which treatment ...

AI-driven single blood cell classification

New method to support physicians in leukemia diagnostics

14-Nov-2019 - For the first time, researchers from Helmholtz Zentrum München and the University Hospital of LMU Munich show that deep learning algorithms perform similar to human experts when classifying blood samples from patients suffering from acute myeloid leukemia (AML). Their proof of concept study paves ...

'Overturning established fact' leads to new new target in MLL-rearranged leukemia

15-Jun-2017 - The human gene MLL is named for the mixed lineage leukemia it creates. Specifically, the gene may break apart and fuse with parts from one of a number of other genes on other chromosomes to create cancer-causing translocations. These translocations make new proteins that have never been seen by ...

Taking a closer look at genetic switches in cancer

24-May-2017 - Many things go wrong in cells during the development of cancer. At the heart of the chaos are often genetic switches that control the production of new cells. In a particularly aggressive form of leukemia, called acute myeloid leukemia, a genetic switch that regulates the maturation of blood stem ...

Genzyme Releases Two New Molecular Tests for Acute Myelogenous Leukemia

Tools Improve Treatment Management of AML Patients

19-May-2006 - Genzyme Corporation announced the availability of two new molecular tests for acute myelogenous leukemia (AML) with the launch of FLT3 Mutation Analysis and WT1 RQ-PCR. FLT3 mutations are considered a prognostic indicator of poor survival and response to standard chemotherapies. The WT1 RQ PCR ...